首页> 美国卫生研究院文献>Neuropsychiatric Disease and Treatment >Head-to-head comparison of 1-year aripiprazole long-acting injectable (LAI) versus paliperidone LAI in comorbid psychosis and substance use disorder: impact on clinical status substance craving and quality of life

【2h】

Head-to-head comparison of 1-year aripiprazole long-acting injectable (LAI) versus paliperidone LAI in comorbid psychosis and substance use disorder: impact on clinical status substance craving and quality of life

机译：一年期阿立哌唑长效注射剂（LAI）与帕潘立酮LAI在合并症精神病和药物滥用中的面对面比较：对临床状态药物渴望和生活质量的影响

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

BackgroundTo overcome nonadherence in patients with psychosis switch to long-acting injectable (LAI) antipsychotic formulations is adopted. Most oral versus LAI comparisons showed similar antipsychotic responses. Psychoses often overlap with substance use disorder (SUD). Head-to-head LAI comparisons have hitherto focused only on non-comorbid populations.

机译：背景技术为了克服精神病患者的不依从性，改用长效可注射（LAI）抗精神病药物。大多数口服和LAI比较显示出相似的抗精神病反应。精神病经常与物质使用障碍（SUD）重叠。迄今为止，头对头的LAI比较仅针对非共病人群。

著录项

期刊名称 Neuropsychiatric Disease and Treatment
作者
Ilaria Cuomo; Georgios D Kotzalidis; Simone de Persis; Daria Piacentino; Filippo Perrini; Emanuela Amici; Sergio De Filippis;
展开▼
作者单位

展开▼
年(卷),期 2018(14),-1
年度 2018
页码 1645–1656
总页数 12
原文格式 PDF
正文语种
中图分类神经病学;精神病学;
关键词
psychosis schizophrenia spectrum and other psychotic disorders bipolar disorder long-acting injectable antipsychotic drugs aripiprazole once-monthly paliperidone once-monthly;

机译：精神病;精神分裂症谱图和其他精神病;双相情感障碍;长效抗精神病药;阿立哌唑每月一次;帕潘立酮每月一次;

相似文献

外文文献

1. Head-to-head comparison of 1-year aripiprazole long-acting injectable (LAI) versus paliperidone LAI in comorbid psychosis and substance use disorder: impact on clinical status, substance craving, and quality of life [J] . Ilaria Cuomo, Georgios D Kotzalidis, Simone de Persis, Neuropsychiatric Disease and Treatment . 2018,第1期

机译：一年期阿立哌唑长效注射剂（LAI）与帕潘立酮LAI在合并症，精神病和药物滥用中的面对面比较：对临床状况，药物渴望和生活质量的影响
2. Effects of 1-year aripiprazole once-monthly vs. paliperidone palmitate on clinical status, functioning, and quality-of-life of patients with bipolar disorder [J] . European neuropsychopharmacology: the journal of the European College of Neuropsychopharmacology . 2019,第S6期

机译：1年AripiPrazole的影响每月对帕帕里酮棕榈酸的临床地位，运作和生活质量和生活质量
3. Methodological challenges in indirect treatment comparisons: spotlight on a recent comparison of long-acting injectable aripiprazole versus paliperidone palmitate in the treatment of schizophrenia [J] . Singh Arun, Gopal Srihari, Kim Edward, International clinical psychopharmacology . 2018,第4期

机译：间接治疗比较的方法论挑战：近期对长效可注射阿里希哌唑比较帕利替酮棕榈酸治疗精神分裂症的影响
4. S200. COMPARISON BETWEEN LONG-ACTING INJECTABLE ARIPIPRAZOLE VERSUS PALIPERIDONE PALMITATE IN THE TREATMENT OF SCHIZOPHRENIA: SYSTEMATIC REVIEW AND INDIRECT TREATMENT COMPARISON [O] . 2020

机译：S200。长期治疗可注射的阿立哌唑与帕利哌酮棕榈酸酯治疗精神分裂症的比较：系统评价和间接治疗比较
5. S200. COMPARISON BETWEEN LONG-ACTING INJECTABLE ARIPIPRAZOLE VERSUS PALIPERIDONE PALMITATE IN THE TREATMENT OF SCHIZOPHRENIA: SYSTEMATIC REVIEW AND INDIRECT TREATMENT COMPARISON [O] . 2020

机译：S200。长效可注射阿里哌唑与Paliperidone棕榈酸盐在精神分裂症治疗中的比较：系统评价与间接治疗比较

Head-to-head comparison of 1-year aripiprazole long-acting injectable (LAI) versus paliperidone LAI in comorbid psychosis and substance use disorder: impact on clinical status substance craving and quality of life

摘要

著录项

相似文献

相关主题

期刊订阅